Brief: Cardiol Therapeutics Says It Has Exceeded 50% Enrollment In Its Phase II Trial In Acute Myocarditis
09/01/2024 12:40
Jan 9 (Reuters) - Cardiol Therapeutics Inc CRDL.TO :
* CARDIOL THERAPEUTICS INC: IT HAS EXCEEDED 50% ENROLLMENT
IN ITS
PHASE II ARCHER TRIAL IN ACUTE MYOCARDITIS
Further company coverage: CRDL.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cardiol Therapeutics
See all newsBrief: Cardiol Therapeutics Initiated Pivotal Phase Iii Maveric Trial Of Cardiolrx In Recurrent Pericarditis
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 08:11 AM
Brief: Cardiol Therapeutics Files For Mixed Shelf Of Up To $150 Million
Brief: Cardiol Therapeutics Enrolls First Patient In Pivotal Phase III Maveric Trial In Recurrent Pericarditis